Corcept Therapeutics (CORT) Financials

$76.22 +1.40 (+1.87%)

As of 05/20/2025 04:00 PM Eastern

Annual Income Statements for Corcept Therapeutics

This table shows Corcept Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	140	105	101	113	106	94	75	129	8.14	-6.41
Consolidated Net Income / (Loss)	141	106	101	113	106	94	75	129	8.14	-6.41
Net Income / (Loss) Continuing Operations	141	106	101	113	106	94	75	129	8.14	-6.41
Total Pre-Tax Income	161	125	116	125	132	117	92	53	8.14	-6.41
Total Operating Income	137	107	113	124	128	112	89	53	10	-3.44
Total Gross Profit	664	476	396	361	348	301	246	156	79	49
Total Revenue	675	482	402	366	354	306	251	159	81	50
Operating Revenue	675	482	402	366	354	306	251	159	81	50
Total Cost of Revenue	11	6.48	5.39	5.28	5.58	5.50	5.22	3.55	2.06	1.36
Operating Cost of Revenue	11	6.48	5.39	5.28	5.58	5.50	5.22	3.55	2.06	1.36
Total Operating Expenses	527	369	284	236	220	189	157	103	69	52
Selling, General & Admin Expense	280	184	153	122	105	100	81	62	45	37
Research & Development Expense	247	184	131	114	115	89	75	40	24	15
Other Special Charges / (Income)	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-
Total Other Income / (Expense), net	25	17	3.56	0.53	3.40	5.07	2.66	-0.05	-2.04	-2.97
Income Tax Expense	20	18	15	12	26	22	17	-76	0.00	0.00
Basic Earnings per Share	$1.35	$1.02	$0.95	$0.97	$0.92	$0.82	$0.65	$1.14	$0.07	($0.06)
Weighted Average Basic Shares Outstanding	103.23M	103.56M	106.79M	115.65M	115.41M	114.35M	115.34M	113.53M	110.57M	106.88M
Diluted Earnings per Share	$1.23	$0.94	$0.87	$0.89	$0.85	$0.77	$0.60	$1.04	$0.07	($0.06)
Weighted Average Diluted Shares Outstanding	113.48M	111.74M	115.97M	125.96M	124.19M	122.57M	126.69M	124.52M	116.14M	106.88M
Weighted Average Basic & Diluted Shares Outstanding	105.50M	103.52M	107.90M	105.96M	117.31M	114.90M	116M	113.30M	116.30M	106.80M

This table shows Corcept Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	20	30	47	35	28	31	31	27	16	16	35
Consolidated Net Income / (Loss)	21	31	47	35	28	31	31	28	16	17	35
Net Income / (Loss) Continuing Operations	21	31	47	35	28	31	31	28	16	17	35
Total Pre-Tax Income	9.62	32	53	42	35	37	36	33	18	24	33
Total Operating Income	3.42	25	47	36	30	32	31	30	15	22	32
Total Gross Profit	155	179	180	161	144	134	122	116	104	102	100
Total Revenue	157	182	183	164	147	135	124	118	106	103	102
Operating Revenue	157	182	183	164	147	135	124	118	106	103	102
Total Cost of Revenue	2.40	2.96	2.87	2.52	2.54	1.88	1.65	1.57	1.39	1.48	1.34
Operating Cost of Revenue	2.40	2.96	2.87	2.52	2.54	1.88	1.65	1.57	1.39	1.48	1.34
Total Operating Expenses	151	154	133	126	115	102	91	87	89	79	68
Selling, General & Admin Expense	91	83	74	67	56	47	45	43	49	42	35
Research & Development Expense	61	70	59	59	59	55	46	43	41	37	33
Total Other Income / (Expense), net	6.20	6.70	6.35	6.00	5.49	5.14	5.21	3.35	3.58	1.78	1.07
Income Tax Expense	-11	1.22	5.73	6.11	7.23	5.45	5.01	5.40	2.56	7.68	-1.60
Basic Earnings per Share	$0.19	$0.29	$0.45	$0.34	$0.27	$0.29	$0.31	$0.27	$0.15	$0.15	$0.32
Weighted Average Basic Shares Outstanding	104.11M	103.23M	103.37M	103.12M	102.79M	103.56M	102.01M	101.96M	107.89M	106.79M	107.13M
Diluted Earnings per Share	$0.17	$0.25	$0.41	$0.32	$0.25	$0.27	$0.28	$0.25	$0.14	$0.13	$0.30
Weighted Average Diluted Shares Outstanding	119.82M	113.48M	113.72M	111.24M	109.92M	111.74M	111.10M	109.59M	115.43M	115.97M	116.62M
Weighted Average Basic & Diluted Shares Outstanding	106.04M	105.50M	104.78M	104.49M	104.11M	103.52M	103.08M	102.55M	101.58M	107.90M	107.65M

This table details how cash moves in and out of Corcept Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	-7.89	69	-11	1.43	45	-10	11	-20	11	16
Net Cash From Operating Activities	198	127	120	168	152	136	116	61	18	3.13
Net Cash From Continuing Operating Activities	198	127	120	168	152	136	116	61	18	3.13
Net Income / (Loss) Continuing Operations	141	106	101	113	106	94	75	129	8.14	-6.41
Consolidated Net Income / (Loss)	141	106	101	113	106	94	75	129	8.14	-6.41
Depreciation Expense	0.80	1.04	1.26	1.07	0.53	0.70	0.24	0.11	0.09	0.16
Amortization Expense	-10	-7.81	3.57	7.49	3.02	-0.27	-1.72	0.01	0.02	0.02
Non-Cash Adjustments To Reconcile Net Income	74	54	42	40	39	28	24	14	8.99	8.86
Changes in Operating Assets and Liabilities, net	-7.62	-27	-28	7.17	3.19	14	18	-82	1.16	0.50
Net Cash From Investing Activities	-178	91	-114	136	-119	-118	-91	-73	-0.19	-0.02
Net Cash From Continuing Investing Activities	-178	91	-114	136	-119	-118	-91	-73	-0.19	-0.02
Purchase of Property, Plant & Equipment	-2.17	-0.14	-0.41	-0.47	-1.24	-1.09	-0.30	-0.42	-0.19	-0.02
Purchase of Investments	-588	-329	-355	-313	-420	-299	-233	-103	0.00	0.00
Sale and/or Maturity of Investments	413	420	241	449	302	182	143	30	0.00	-
Net Cash From Financing Activities	-28	-149	-17	-303	12	-29	-14	-7.95	-7.10	13
Net Cash From Continuing Financing Activities	-28	-149	-17	-303	12	-29	-14	-7.95	-7.10	13
Repurchase of Preferred Equity	0.00	-145	0.00	-	-	-	-	-	-	-
Repurchase of Common Equity	-16	0.00	0.00	-296	-9.95	-31	-24	0.00	0.00	-
Issuance of Common Equity	9.62	5.81	4.38	16	23	8.42	9.32	7.18	7.68	-
Other Financing Activities, net	-22	-9.11	-22	-23	-1.07	-6.09	0.00	0.00	-	22
Cash Income Taxes Paid	60	48	40	9.10	11	6.74	1.35	0.38	0.04	0.06

This table details how cash moves in and out of Corcept Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-38	-9.62	8.70	-21	14	24	-61	-128	234	16	15
Net Cash From Operating Activities	5.13	59	74	41	24	5.89	53	42	26	33	34
Net Cash From Continuing Operating Activities	5.13	59	74	41	24	5.89	53	42	26	33	34
Net Income / (Loss) Continuing Operations	21	31	47	35	28	31	31	28	16	17	35
Consolidated Net Income / (Loss)	21	31	47	35	28	31	31	28	16	17	35
Depreciation Expense	0.29	0.28	0.32	0.13	0.07	0.21	0.23	0.42	0.17	0.66	0.20
Amortization Expense	0.18	-11	0.18	0.07	0.11	-3.14	-5.88	0.52	0.69	-0.17	0.81
Non-Cash Adjustments To Reconcile Net Income	11	46	19	9.30	-0.19	13	19	14	9.05	9.12	11
Changes in Operating Assets and Liabilities, net	-27	-6.79	6.98	-3.81	-3.99	-36	8.49	0.15	0.17	7.18	-12
Net Cash From Investing Activities	-3.17	-64	-44	-60	-9.01	17	-110	-24	207	-17	-4.79
Net Cash From Continuing Investing Activities	-3.17	-64	-44	-60	-9.01	17	-110	-24	207	-17	-4.79
Purchase of Property, Plant & Equipment	-0.10	-0.12	-1.64	-	-	-	-0.04	-	-	-0.03	-0.35
Purchase of Investments	-115	-145	-223	-143	-78	-30	-210	-89	0.00	-97	-79
Sale and/or Maturity of Investments	112	80	181	83	69	47	100	65	207	79	74
Net Cash From Financing Activities	-40	-4.56	-21	-2.15	-0.54	0.77	-3.92	-146	0.18	-0.06	-14
Net Cash From Continuing Financing Activities	-40	-4.56	-21	-2.15	-0.54	0.77	-3.92	-146	0.18	-0.06	-14
Repurchase of Common Equity	-27	-	-12	-3.48	-0.48	-	-	-	0.00	-	-
Issuance of Common Equity	1.72	2.42	2.27	3.24	1.69	1.76	1.14	1.50	1.41	0.79	1.66
Other Financing Activities, net	-14	-6.99	-12	-1.91	-1.76	-1.00	-5.06	-1.82	-1.23	-0.85	-16

This table presents Corcept Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	841	622	583	424	572	412	312	221	69	52
Total Current Assets	472	459	499	266	479	307	237	124	66	49
Cash & Equivalents	128	136	66	78	76	31	42	31	52	40
Short-Term Investments	256	233	365	146	365	245	165	58	0.00	-
Accounts Receivable	54	41	31	28	26	20	18	28	9.86	6.22
Inventories, net	12	7.73	6.10	4.99	4.91	5.42	4.73	4.58	2.33	1.68
Prepaid Expenses	22	28	16	10	6.70	6.04	7.74	2.67	1.96	0.64
Other Current Assets	0.00	14	14	0.00	-	-	-	-	-	-
Plant, Property, & Equipment, net	2.69	0.20	0.63	1.00	1.68	1.05	0.66	0.52	0.21	0.10
Total Noncurrent Assets	366	163	84	156	92	104	74	96	2.86	2.82
Long-Term Investments	220	57	4.95	112	36	39	0.00	15	0.00	-
Noncurrent Deferred & Refundable Income Taxes	131	91	61	27	32	46	63	77	0.00	-
Other Noncurrent Operating Assets	16	15	17	17	24	19	12	3.85	2.86	2.82
Total Liabilities & Shareholders' Equity	841	622	583	424	572	412	312	221	69	52
Total Liabilities	161	115	82	48	48	41	36	30	27	33
Total Current Liabilities	141	105	72	48	47	39	36	30	27	21
Accounts Payable	15	17	12	6.91	11	7.54	8.27	8.58	2.29	1.33
Accrued Expenses	125	87	59	40	35	30	27	21	10	4.43
Other Current Liabilities	0.83	0.15	1.14	0.53	2.05	1.56	0.00	-	-	-
Total Noncurrent Liabilities	20	10	9.10	0.41	0.90	2.29	0.24	0.00	0.00	13
Noncurrent Deferred Revenue	14	10	9.10	0.41	0.40	0.39	0.24	0.00	-	-
Other Noncurrent Operating Liabilities	6.11	0.00	-	-	0.50	1.90	0.00	-	-	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	680	507	502	376	523	371	276	191	41	18
Total Preferred & Common Equity	680	507	502	376	523	371	276	191	41	18
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	680	507	502	376	523	371	276	191	41	18
Common Stock	832	739	662	591	516	457	417	384	364	349
Retained Earnings	544	403	296	195	82	-24	-118	-193	-322	-330
Treasury Stock	-696	-635	-456	-410	-76	-63	-24	0.00	-	-
Accumulated Other Comprehensive Income / (Loss)	-0.22	0.61	-0.87	-0.23	0.42	0.26	-0.07	-0.08	0.00	-

This table presents Corcept Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	846	784	715	656	594	525	618	533
Total Current Assets	439	467	561	503	432	433	534	452
Cash & Equivalents	90	137	129	150	112	172	300	50
Short-Term Investments	233	243	345	261	243	191	165	346
Accounts Receivable	62	60	54	62	35	33	33	29
Inventories, net	14	8.05	8.35	7.19	7.51	6.92	6.41	6.05
Prepaid Expenses	40	19	26	24	20	16	16	21
Plant, Property, & Equipment, net	2.54	2.93	1.47	0.13	0.30	0.41	0.46	0.80
Total Noncurrent Assets	405	314	152	152	162	92	83	80
Long-Term Investments	248	167	19	40	60	0.00	0.00	4.90
Noncurrent Deferred & Refundable Income Taxes	144	127	112	98	87	78	68	57
Other Noncurrent Operating Assets	13	20	21	14	15	13	15	18
Total Liabilities & Shareholders' Equity	846	784	715	656	594	525	618	533
Total Liabilities	163	145	118	108	132	103	88	60
Total Current Liabilities	143	126	101	97	122	93	79	53
Accounts Payable	28	19	19	13	17	7.98	11	8.18
Accrued Expenses	114	107	81	85	105	85	67	43
Other Current Liabilities	0.98	0.43	0.04	0.08	0.23	0.30	0.58	1.71
Total Noncurrent Liabilities	20	19	18	11	10	9.95	9.40	6.82
Noncurrent Deferred Revenue	14	13	12	11	10	9.95	9.40	6.82
Other Noncurrent Operating Liabilities	5.85	6.36	5.63	-	-	-	-	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	683	639	596	548	462	422	530	473
Total Preferred & Common Equity	683	639	596	548	462	422	530	473
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	683	639	596	548	462	422	530	473
Common Stock	863	806	781	758	723	696	680	649
Retained Earnings	564	513	466	430	371	340	312	280
Treasury Stock	-745	-682	-	-641	-	-	-463	-
Accumulated Other Comprehensive Income / (Loss)	0.69	1.57	0.08	0.26	-0.23	0.05	-0.15	-2.38

This table displays calculated financial ratios and metrics derived from Corcept Therapeutics' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	39.94%	20.04%	9.80%	3.42%	15.46%	21.99%	57.82%	95.77%	61.72%	89.39%
EBITDA Growth	26.70%	-14.43%	-12.06%	-1.17%	15.40%	29.16%	71.31%	541.68%	232.37%	77.30%
EBIT Growth	27.66%	-4.75%	-9.90%	-5.01%	12.79%	26.61%	74.51%	548.72%	227.03%	76.80%
NOPAT Growth	30.99%	-7.01%	-12.25%	8.49%	14.63%	23.01%	-43.33%	1,169.69%	522.35%	87.53%
Net Income Growth	33.04%	4.66%	-9.86%	6.13%	12.56%	24.89%	-41.60%	1,486.27%	227.03%	79.58%
EPS Growth	30.85%	8.05%	-2.25%	4.71%	10.39%	28.33%	-42.31%	1,385.71%	216.67%	80.65%
Operating Cash Flow Growth	55.91%	5.58%	-28.33%	10.48%	11.65%	17.68%	89.82%	231.33%	487.57%	111.43%
Free Cash Flow Firm Growth	65.44%	3.08%	-38.32%	5.14%	9.05%	13.49%	94.54%	316.87%	754.66%	92.96%
Invested Capital Growth	-6.01%	24.66%	63.08%	-13.89%	-16.86%	-19.17%	-20.50%	1,829.07%	-18.88%	-11.12%
Revenue Q/Q Growth	7.40%	7.19%	1.06%	3.71%	-0.61%	7.38%	5.70%	22.72%	12.20%	13.43%
EBITDA Q/Q Growth	-9.88%	6.08%	-12.10%	5.49%	-3.17%	9.75%	2.67%	45.97%	18.83%	21.92%
EBIT Q/Q Growth	-4.47%	9.35%	-11.17%	4.98%	-4.12%	9.91%	4.60%	46.01%	19.30%	21.57%
NOPAT Q/Q Growth	-2.03%	14.22%	-14.65%	5.92%	-2.36%	8.55%	-50.73%	258.67%	49.19%	57.86%
Net Income Q/Q Growth	-0.43%	16.05%	-13.17%	5.69%	-3.10%	8.49%	-50.30%	264.86%	80.81%	43.10%
EPS Q/Q Growth	-1.60%	17.50%	-13.00%	7.23%	-3.41%	6.94%	-50.41%	258.62%	40.00%	50.00%
Operating Cash Flow Q/Q Growth	36.92%	-17.80%	-11.76%	9.35%	-8.09%	24.67%	-2.83%	50.01%	2.26%	228.49%
Free Cash Flow Firm Q/Q Growth	60.06%	-28.53%	-16.98%	11.58%	-11.81%	31.84%	-4.55%	64.22%	-1.36%	70.59%
Invested Capital Q/Q Growth	-16.19%	73.61%	-9.67%	-11.23%	2.16%	-17.21%	9.94%	802.09%	113.91%	-16.66%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	98.39%	98.66%	98.66%	98.56%	98.42%	98.20%	97.92%	97.77%	97.47%	97.29%
EBITDA Margin	18.87%	20.84%	29.23%	36.50%	38.19%	38.21%	36.09%	33.24%	10.14%	-12.39%
Operating Margin	20.29%	22.24%	28.03%	34.01%	36.23%	36.41%	35.62%	33.20%	12.52%	-6.85%
EBIT Margin	20.29%	22.24%	28.03%	34.16%	37.19%	38.07%	36.68%	33.17%	10.01%	-12.74%
Profit (Net Income) Margin	20.92%	22.00%	25.24%	30.74%	29.96%	30.73%	30.01%	81.11%	10.01%	-12.74%
Tax Burden Percent	87.44%	85.21%	87.29%	90.01%	80.55%	80.72%	81.83%	244.52%	100.00%	100.00%
Interest Burden Percent	117.92%	116.10%	103.16%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	12.56%	14.79%	12.71%	9.99%	19.45%	19.28%	18.17%	-144.52%	0.00%	0.00%
Return on Invested Capital (ROIC)	151.84%	124.78%	186.88%	259.22%	201.87%	144.15%	93.85%	282.65%	202.31%	-40.82%
ROIC Less NNEP Spread (ROIC-NNEP)	147.67%	121.36%	186.07%	259.11%	201.18%	142.59%	92.45%	282.82%	210.49%	201.25%
Return on Net Nonoperating Assets (RNNOA)	-128.03%	-103.73%	-163.77%	-234.20%	-178.17%	-115.04%	-61.55%	-171.50%	-175.12%	-43.99%
Return on Equity (ROE)	23.81%	21.05%	23.11%	25.03%	23.70%	29.11%	32.31%	111.15%	27.19%	-84.82%
Cash Return on Invested Capital (CROIC)	158.03%	102.82%	138.92%	274.15%	220.29%	165.36%	116.69%	102.36%	223.15%	-29.05%
Operating Return on Assets (OROA)	18.73%	17.81%	22.37%	25.11%	26.75%	32.23%	34.63%	36.51%	13.49%	-14.81%
Return on Assets (ROA)	19.32%	17.62%	20.14%	22.60%	21.55%	26.02%	28.34%	89.27%	13.49%	-14.81%
Return on Common Equity (ROCE)	23.81%	21.05%	23.11%	25.03%	23.70%	29.11%	32.31%	111.15%	27.19%	-84.82%
Return on Equity Simple (ROE_SIMPLE)	20.78%	20.95%	20.21%	29.94%	20.26%	25.37%	27.33%	67.61%	19.67%	-34.64%
Net Operating Profit after Tax (NOPAT)	120	91	98	112	103	90	73	129	10	-2.41
NOPAT Margin	17.74%	18.95%	24.46%	30.61%	29.18%	29.39%	29.15%	81.18%	12.52%	-4.79%
Net Nonoperating Expense Percent (NNEP)	4.17%	3.42%	0.80%	0.12%	0.69%	1.57%	1.40%	-0.17%	-8.19%	-242.08%
Return On Investment Capital (ROIC_SIMPLE)	17.62%	18.04%	19.59%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	1.61%	1.34%	1.34%	1.44%	1.58%	1.80%	2.08%	2.23%	2.53%	2.71%
SG&A Expenses to Revenue	41.53%	38.20%	38.04%	33.43%	29.76%	32.75%	32.35%	39.21%	55.63%	73.48%
R&D to Revenue	36.57%	38.22%	32.60%	31.11%	32.43%	29.04%	29.95%	25.36%	29.32%	30.66%
Operating Expenses to Revenue	78.10%	76.42%	70.63%	64.54%	62.19%	61.79%	62.30%	64.57%	84.95%	104.14%
Earnings before Interest and Taxes (EBIT)	137	107	113	125	132	117	92	53	8.14	-6.41
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	127	101	117	134	135	117	91	53	8.25	-6.23
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.77	6.61	4.36	6.08	5.81	3.73	5.59	10.79	19.48	29.28
Price to Tangible Book Value (P/TBV)	7.77	6.61	4.36	6.08	5.81	3.73	5.59	10.79	19.48	29.28
Price to Revenue (P/Rev)	7.82	6.94	5.44	6.25	8.59	4.51	6.14	12.95	9.91	10.77
Price to Earnings (P/E)	37.78	31.74	21.59	20.32	28.67	14.68	20.46	15.96	99.03	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.65%	3.15%	4.63%	4.92%	3.49%	6.81%	4.89%	6.26%	1.01%	0.00%
Enterprise Value to Invested Capital (EV/IC)	61.19	35.95	26.83	48.76	55.17	19.11	19.33	22.51	170.67	95.17
Enterprise Value to Revenue (EV/Rev)	6.93	6.06	4.35	5.33	7.24	3.48	5.32	12.29	9.46	10.52
Enterprise Value to EBITDA (EV/EBITDA)	36.72	29.08	14.90	14.60	18.96	9.12	14.73	36.98	93.26	0.00
Enterprise Value to EBIT (EV/EBIT)	34.15	27.24	15.53	15.60	19.47	9.15	14.50	37.06	94.50	0.00
Enterprise Value to NOPAT (EV/NOPAT)	39.05	31.97	17.80	17.41	24.81	11.85	18.24	15.14	75.57	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	23.61	23.01	14.54	11.62	16.86	7.84	11.55	32.12	41.83	168.93
Enterprise Value to Free Cash Flow (EV/FCFF)	37.52	38.80	23.94	16.46	22.74	10.33	14.67	41.81	68.51	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.35	1.49
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.68
Financial Leverage	-0.87	-0.85	-0.88	-0.90	-0.89	-0.81	-0.67	-0.61	-0.83	-0.22
Leverage Ratio	1.23	1.19	1.15	1.11	1.10	1.12	1.14	1.25	2.02	5.73
Compound Leverage Factor	1.45	1.39	1.18	1.11	1.10	1.12	1.14	1.25	2.02	5.73
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	26.17%	59.78%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	26.17%	32.54%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	27.24%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	73.83%	40.22%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.78	-4.41
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-4.47	2.08
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.01
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.44	-11.41
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-3.62	5.37
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-5.20
Altman Z-Score	22.40	20.43	18.99	31.71	40.17	22.55	27.87	42.62	13.35	2.03
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.35	4.39	6.89	5.60	10.08	7.91	6.66	4.20	2.40	2.35
Quick Ratio	3.11	3.92	6.38	5.28	9.83	7.62	6.31	3.95	2.24	2.23
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	125	75	73	118	113	103	91	47	11	-1.72
Operating Cash Flow to CapEx	9,119.11%	91,394.96%	29,133.90%	35,797.87%	12,275.44%	12,510.75%	38,813.76%	14,542.96%	9,479.90%	18,411.76%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.92	0.80	0.80	0.74	0.72	0.85	0.94	1.10	1.35	1.16
Accounts Receivable Turnover	14.20	13.37	13.70	13.60	15.34	16.34	10.98	8.37	10.11	10.53
Inventory Turnover	1.08	0.94	0.97	1.07	1.08	1.08	1.12	1.03	1.03	0.94
Fixed Asset Turnover	468.13	1,165.16	491.57	273.42	259.72	359.51	428.38	440.39	536.77	301.11
Accounts Payable Turnover	0.66	0.44	0.57	0.60	0.62	0.70	0.62	0.65	1.14	0.85
Days Sales Outstanding (DSO)	25.71	27.31	26.65	26.84	23.79	22.34	33.26	43.63	36.09	34.68
Days Inventory Outstanding (DIO)	337.80	389.44	375.78	342.05	337.86	336.75	325.74	354.58	355.69	387.39
Days Payable Outstanding (DPO)	549.61	827.09	639.99	603.45	591.47	523.99	589.49	558.13	320.57	430.57
Cash Conversion Cycle (CCC)	-186.11	-410.34	-237.56	-234.56	-229.82	-164.90	-230.50	-159.93	71.21	-8.50
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	76	81	65	40	46	56	69	87	4.51	5.56
Invested Capital Turnover	8.56	6.58	7.64	8.47	6.92	4.90	3.22	3.48	16.16	8.52
Increase / (Decrease) in Invested Capital	-4.88	16	25	-6.45	-9.42	-13	-18	82	-1.05	-0.70
Enterprise Value (EV)	4,676	2,923	1,750	1,950	2,562	1,067	1,336	1,957	769	529
Market Capitalization	5,280	3,348	2,186	2,286	3,039	1,383	1,543	2,061	806	542
Book Value per Share	$6.49	$4.92	$4.66	$3.25	$4.50	$3.25	$2.39	$1.67	$0.37	$0.17
Tangible Book Value per Share	$6.49	$4.92	$4.66	$3.25	$4.50	$3.25	$2.39	$1.67	$0.37	$0.17
Total Capital	680	507	502	376	523	371	276	191	56	46
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	15	27
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13
Net Debt	-603	-425	-437	-336	-477	-315	-207	-104	-37	-13
Capital Expenditures (CapEx)	2.17	0.14	0.41	0.47	1.24	1.09	0.30	0.42	0.19	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-53	-14	-4.91	-4.61	-9.69	-7.45	-5.51	5.87	1.44	2.63
Debt-free Net Working Capital (DFNWC)	331	354	427	219	431	269	201	95	53	43
Net Working Capital (NWC)	331	354	427	219	431	269	201	95	38	28
Net Nonoperating Expense (NNE)	-21	-15	-3.10	-0.48	-2.74	-4.09	-2.17	0.12	2.04	4.00
Net Nonoperating Obligations (NNO)	-603	-425	-437	-336	-477	-315	-207	-104	-37	-13
Total Depreciation and Amortization (D&A)	-9.60	-6.77	4.83	8.56	3.54	0.43	-1.49	0.12	0.11	0.18
Debt-free, Cash-free Net Working Capital to Revenue	-7.78%	-2.92%	-1.22%	-1.26%	-2.74%	-2.43%	-2.19%	3.69%	1.77%	5.24%
Debt-free Net Working Capital to Revenue	49.01%	73.41%	106.20%	59.82%	121.80%	87.61%	80.10%	59.43%	65.15%	85.65%
Net Working Capital to Revenue	49.01%	73.41%	106.20%	59.82%	121.80%	87.61%	80.10%	59.43%	47.12%	55.89%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.35	$1.02	$0.95	$0.97	$0.92	$0.82	$0.65	$1.14	$0.07	($0.06)
Adjusted Weighted Average Basic Shares Outstanding	103.23M	103.56M	106.79M	115.65M	115.41M	114.35M	115.34M	113.53M	110.57M	109.66M
Adjusted Diluted Earnings per Share	$1.23	$0.94	$0.87	$0.89	$0.85	$0.77	$0.60	$1.04	$0.07	($0.06)
Adjusted Weighted Average Diluted Shares Outstanding	113.48M	111.74M	115.97M	125.96M	124.19M	122.57M	126.69M	124.52M	116.14M	109.66M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.82	$0.00	$0.00	$0.07	($0.06)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	105.50M	103.52M	107.90M	105.96M	117.31M	114.59M	114.72M	114.83M	112.94M	106.88M
Normalized Net Operating Profit after Tax (NOPAT)	120	91	98	112	103	90	73	37	7.13	-2.41
Normalized NOPAT Margin	17.74%	18.95%	24.46%	30.61%	29.18%	29.39%	29.15%	23.24%	8.76%	-4.79%
Pre Tax Income Margin	23.92%	25.82%	28.91%	34.16%	37.19%	38.07%	36.68%	33.17%	10.01%	-12.74%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	11.09%	0.00%	0.00%	263.07%	9.38%	32.89%	31.37%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Corcept Therapeutics' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	7.09%	34.33%	47.69%	39.15%	38.95%	31.39%	21.50%	13.86%	12.77%	4.28%	5.82%
EBITDA Growth	-86.93%	-48.57%	84.46%	17.25%	88.89%	25.06%	-22.48%	-7.12%	-45.36%	-41.39%	-19.63%
EBIT Growth	-88.42%	-20.23%	49.46%	20.31%	98.61%	40.76%	-2.37%	-5.88%	-44.68%	-38.75%	-12.04%
NOPAT Growth	-68.82%	-9.92%	54.56%	22.79%	82.93%	75.34%	-19.71%	-7.98%	-43.71%	-51.90%	10.11%
Net Income Growth	-25.99%	-1.94%	50.47%	28.92%	74.83%	88.06%	-9.18%	0.47%	-30.35%	-47.98%	13.39%
EPS Growth	-32.00%	-7.41%	46.43%	28.00%	78.57%	107.69%	-6.67%	4.17%	-30.00%	-50.00%	25.00%
Operating Cash Flow Growth	-78.41%	907.30%	39.54%	-2.61%	-8.48%	-82.37%	57.24%	134.40%	-26.36%	-32.45%	-30.91%
Free Cash Flow Firm Growth	6.07%	167.94%	-105.36%	-156.32%	25.96%	210.66%	725.34%	52.22%	-130.79%	-125.61%	-79.45%
Invested Capital Growth	16.17%	-6.01%	94.71%	77.84%	50.06%	24.66%	-35.14%	-3.31%	62.46%	63.08%	60.27%
Revenue Q/Q Growth	-13.57%	-0.36%	11.45%	11.57%	8.42%	9.55%	5.00%	11.42%	2.52%	1.31%	-1.60%
EBITDA Q/Q Growth	-73.77%	-68.61%	31.59%	20.59%	1.98%	12.58%	-16.35%	94.28%	-31.64%	-30.22%	0.22%
EBIT Q/Q Growth	-86.48%	-45.79%	30.92%	20.65%	-6.85%	1.58%	5.39%	99.17%	-33.98%	-29.55%	1.60%
NOPAT Q/Q Growth	-69.97%	-41.52%	36.85%	29.75%	-13.25%	0.34%	8.72%	93.29%	-16.84%	-54.05%	24.61%
Net Income Q/Q Growth	-33.17%	-34.88%	33.04%	27.83%	-12.04%	-0.07%	13.99%	73.36%	-4.76%	-51.74%	26.10%
EPS Q/Q Growth	-32.00%	-39.02%	28.13%	28.00%	-7.41%	-3.57%	12.00%	78.57%	7.69%	-56.67%	25.00%
Operating Cash Flow Q/Q Growth	-91.35%	-19.68%	79.27%	73.35%	303.53%	-88.87%	25.12%	62.91%	-22.26%	-0.77%	86.52%
Free Cash Flow Firm Q/Q Growth	-128.63%	1,141.83%	81.39%	-69.23%	-181.67%	-79.16%	95.53%	322.46%	-22.06%	-255.45%	-63.94%
Invested Capital Q/Q Growth	47.18%	-16.19%	-12.13%	7.17%	19.09%	73.61%	-19.74%	-9.57%	-1.07%	-9.67%	19.65%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	98.47%	98.37%	98.43%	98.46%	98.27%	98.61%	98.67%	98.66%	98.69%	98.56%	98.68%
EBITDA Margin	2.47%	8.13%	25.80%	21.85%	20.22%	21.23%	20.66%	25.93%	14.87%	22.30%	32.38%
Operating Margin	2.17%	13.89%	25.53%	21.73%	20.09%	23.39%	25.22%	25.13%	14.06%	21.83%	31.39%
EBIT Margin	2.17%	13.89%	25.53%	21.73%	20.09%	23.39%	25.22%	25.13%	14.06%	21.83%	31.39%
Profit (Net Income) Margin	13.07%	16.90%	25.86%	21.67%	18.91%	23.16%	25.39%	23.39%	15.03%	16.18%	33.96%
Tax Burden Percent	213.63%	96.20%	89.18%	85.32%	79.34%	85.19%	86.24%	83.60%	86.14%	68.68%	104.68%
Interest Burden Percent	281.56%	126.52%	113.62%	116.87%	118.62%	116.23%	116.70%	111.31%	124.11%	107.90%	103.35%
Effective Tax Rate	-113.63%	3.80%	10.82%	14.68%	20.66%	14.81%	13.76%	16.40%	13.86%	31.62%	-4.86%
Return on Invested Capital (ROIC)	30.40%	114.35%	207.34%	130.27%	103.45%	131.17%	164.47%	151.55%	96.14%	114.04%	223.24%
ROIC Less NNEP Spread (ROIC-NNEP)	27.81%	113.10%	206.16%	129.07%	102.50%	130.16%	163.37%	150.80%	95.40%	113.71%	223.00%
Return on Net Nonoperating Assets (RNNOA)	-23.08%	-98.06%	-180.30%	-108.51%	-87.15%	-111.25%	-142.57%	-130.08%	-84.79%	-100.08%	-197.21%
Return on Equity (ROE)	7.32%	16.29%	27.03%	21.76%	16.30%	19.93%	21.90%	21.47%	11.35%	13.97%	26.04%
Cash Return on Invested Capital (CROIC)	89.33%	158.03%	112.84%	76.72%	86.36%	102.82%	177.10%	148.44%	121.83%	138.92%	150.15%
Operating Return on Assets (OROA)	1.98%	12.82%	23.28%	19.98%	16.52%	18.73%	20.14%	21.08%	10.71%	17.42%	22.32%
Return on Assets (ROA)	11.93%	15.61%	23.59%	19.92%	15.54%	18.54%	20.27%	19.61%	11.45%	12.91%	24.14%
Return on Common Equity (ROCE)	7.32%	16.29%	27.03%	21.76%	16.30%	19.93%	21.90%	21.47%	11.35%	13.97%	26.04%
Return on Equity Simple (ROE_SIMPLE)	19.61%	0.00%	22.20%	21.13%	21.54%	0.00%	19.81%	22.44%	17.84%	0.00%	24.67%
Net Operating Profit after Tax (NOPAT)	7.30	24	42	30	23	27	27	25	13	15	33
NOPAT Margin	4.64%	13.36%	22.76%	18.54%	15.94%	19.92%	21.75%	21.01%	12.11%	14.93%	32.92%
Net Nonoperating Expense Percent (NNEP)	2.59%	1.25%	1.18%	1.20%	0.95%	1.02%	1.10%	0.75%	0.74%	0.33%	0.24%
Return On Investment Capital (ROIC_SIMPLE)	1.07%	3.58%	-	-	-	5.32%	-	-	-	3.07%	-
Cost of Revenue to Revenue	1.53%	1.63%	1.57%	1.54%	1.73%	1.39%	1.33%	1.34%	1.31%	1.44%	1.32%
SG&A Expenses to Revenue	57.67%	45.84%	40.40%	40.86%	38.33%	34.82%	36.62%	36.77%	45.97%	41.07%	34.57%
R&D to Revenue	38.63%	38.65%	32.50%	35.86%	39.85%	40.40%	36.83%	36.76%	38.66%	35.66%	32.73%
Operating Expenses to Revenue	96.30%	84.49%	72.90%	76.73%	78.18%	75.23%	73.45%	73.53%	84.63%	76.73%	67.29%
Earnings before Interest and Taxes (EBIT)	3.42	25	47	36	30	32	31	30	15	22	32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3.88	15	47	36	30	29	26	31	16	23	33
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	17.64	7.77	7.57	5.67	4.74	6.61	6.05	5.36	4.41	4.36	5.80
Price to Tangible Book Value (P/TBV)	17.64	7.77	7.57	5.67	4.74	6.61	6.05	5.36	4.41	4.36	5.80
Price to Revenue (P/Rev)	17.58	7.82	7.69	5.94	4.96	6.94	6.21	5.28	5.65	5.44	6.91
Price to Earnings (P/E)	90.94	37.78	34.42	27.07	22.15	31.74	30.77	23.98	24.78	21.59	23.50
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.10%	2.65%	2.91%	3.69%	4.51%	3.15%	3.25%	4.17%	4.03%	4.63%	4.26%
Enterprise Value to Invested Capital (EV/IC)	102.06	61.19	47.03	27.85	22.16	35.95	50.80	32.51	29.01	26.83	32.48
Enterprise Value to Revenue (EV/Rev)	16.75	6.93	6.82	5.07	4.10	6.06	5.29	4.43	4.52	4.35	5.90
Enterprise Value to EBITDA (EV/EBITDA)	113.05	36.72	30.35	24.14	18.74	29.08	25.11	18.57	17.91	14.90	17.55
Enterprise Value to EBIT (EV/EBIT)	103.55	34.15	29.91	22.59	17.60	27.24	24.25	19.19	18.59	15.53	18.49
Enterprise Value to NOPAT (EV/NOPAT)	105.19	39.05	35.09	26.86	21.04	31.97	29.72	22.03	21.20	17.80	20.36
Enterprise Value to Operating Cash Flow (EV/OCF)	63.98	23.61	29.65	23.36	17.19	23.01	15.39	14.02	16.86	14.54	17.20
Enterprise Value to Free Cash Flow (EV/FCFF)	122.80	37.52	55.07	46.47	30.79	38.80	22.57	21.53	29.48	23.94	26.64
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.83	-0.87	-0.87	-0.84	-0.85	-0.85	-0.87	-0.86	-0.89	-0.88	-0.88
Leverage Ratio	1.22	1.23	1.25	1.22	1.18	1.19	1.21	1.18	1.16	1.15	1.10
Compound Leverage Factor	3.44	1.56	1.42	1.42	1.40	1.39	1.41	1.32	1.44	1.24	1.14
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	46.49	21.96	22.39	19.80	17.02	20.03	15.10	15.85	18.23	18.48	30.09
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.07	3.35	3.70	5.57	5.18	4.39	3.54	4.65	6.77	6.89	8.52
Quick Ratio	2.69	3.11	3.49	5.23	4.86	3.92	3.20	4.25	6.31	6.38	8.02
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-8.36	29	-2.80	-15	-8.90	11	52	27	-12	-9.84	6.33
Operating Cash Flow to CapEx	4,930.77%	49,008.26%	4,515.54%	0.00%	0.00%	0.00%	142,997.30%	0.00%	0.00%	107,703.23%	9,586.32%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.91	0.92	0.91	0.92	0.82	0.80	0.80	0.84	0.76	0.80	0.71
Accounts Receivable Turnover	11.12	14.20	13.32	13.19	11.13	13.37	14.05	14.10	13.86	13.70	14.22
Inventory Turnover	1.00	1.08	1.26	1.12	1.12	0.94	0.90	0.94	0.96	0.97	0.95
Fixed Asset Turnover	513.44	468.13	388.96	604.36	1,780.71	1,165.16	816.00	671.61	697.26	491.57	392.33
Accounts Payable Turnover	0.53	0.66	0.56	0.62	0.64	0.44	0.49	0.71	0.54	0.57	0.71
Days Sales Outstanding (DSO)	32.84	25.71	27.39	27.68	32.79	27.31	25.97	25.88	26.34	26.65	25.67
Days Inventory Outstanding (DIO)	365.98	337.80	289.76	324.69	325.27	389.44	406.66	390.07	379.74	375.78	383.11
Days Payable Outstanding (DPO)	687.63	549.61	657.13	584.09	568.62	827.09	746.44	512.29	677.14	639.99	511.37
Cash Conversion Cycle (CCC)	-288.80	-186.11	-339.97	-231.71	-210.56	-410.34	-313.81	-96.33	-271.06	-237.56	-102.59
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	112	76	91	104	97	81	47	58	65	65	72
Invested Capital Turnover	6.55	8.56	9.11	7.03	6.49	6.58	7.56	7.21	7.94	7.64	6.78
Increase / (Decrease) in Invested Capital	16	-4.88	44	45	32	16	-25	-2.00	25	25	27
Enterprise Value (EV)	11,480	4,676	4,288	2,890	2,146	2,923	2,379	1,897	1,872	1,750	2,345
Market Capitalization	12,051	5,280	4,836	3,383	2,597	3,348	2,794	2,260	2,337	2,186	2,746
Book Value per Share	$6.48	$6.49	$6.11	$5.73	$5.33	$4.92	$4.50	$4.15	$4.91	$4.66	$4.42
Tangible Book Value per Share	$6.48	$6.49	$6.11	$5.73	$5.33	$4.92	$4.50	$4.15	$4.91	$4.66	$4.42
Total Capital	683	680	639	596	548	507	462	422	530	502	473
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-571	-603	-548	-492	-451	-425	-415	-363	-465	-437	-401
Capital Expenditures (CapEx)	0.10	0.12	1.64	0.00	0.00	0.00	0.04	0.00	0.00	0.03	0.35
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-27	-53	-40	-13	-4.60	-14	-46	-24	-10	-4.91	3.07
Debt-free Net Working Capital (DFNWC)	295	331	341	460	406	354	310	340	455	427	399
Net Working Capital (NWC)	295	331	341	460	406	354	310	340	455	427	399
Net Nonoperating Expense (NNE)	-13	-6.45	-5.66	-5.12	-4.36	-4.38	-4.49	-2.80	-3.08	-1.29	-1.06
Net Nonoperating Obligations (NNO)	-571	-603	-548	-492	-451	-425	-415	-363	-465	-437	-401
Total Depreciation and Amortization (D&A)	0.46	-10	0.50	0.20	0.18	-2.92	-5.64	0.94	0.86	0.49	1.00
Debt-free, Cash-free Net Working Capital to Revenue	-3.99%	-7.78%	-6.30%	-2.29%	-0.88%	-2.92%	-10.13%	-5.54%	-2.42%	-1.22%	0.77%
Debt-free Net Working Capital to Revenue	43.10%	49.01%	54.21%	80.77%	77.58%	73.41%	68.81%	79.30%	109.96%	106.20%	100.43%
Net Working Capital to Revenue	43.10%	49.01%	54.21%	80.77%	77.58%	73.41%	68.81%	79.30%	109.96%	106.20%	100.43%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.19	$0.29	$0.45	$0.34	$0.27	$0.29	$0.31	$0.27	$0.15	$0.15	$0.32
Adjusted Weighted Average Basic Shares Outstanding	104.11M	103.23M	103.37M	103.12M	102.79M	103.56M	102.01M	101.96M	107.89M	106.79M	107.13M
Adjusted Diluted Earnings per Share	$0.17	$0.25	$0.41	$0.32	$0.25	$0.27	$0.28	$0.25	$0.14	$0.13	$0.30
Adjusted Weighted Average Diluted Shares Outstanding	119.82M	113.48M	113.72M	111.24M	109.92M	111.74M	111.10M	109.59M	115.43M	115.97M	116.62M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	106.04M	105.50M	104.78M	104.49M	104.11M	103.52M	103.08M	102.55M	101.58M	107.90M	107.65M
Normalized Net Operating Profit after Tax (NOPAT)	2.39	24	42	30	23	27	27	25	13	15	22
Normalized NOPAT Margin	1.52%	13.36%	22.76%	18.54%	15.94%	19.92%	21.75%	21.01%	12.11%	14.93%	21.97%
Pre Tax Income Margin	6.12%	17.57%	29.00%	25.40%	23.84%	27.18%	29.44%	27.97%	17.45%	23.56%	32.44%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	31.81%	11.09%	113.59%	118.57%	123.62%	0.00%	0.00%	0.00%	0.00%	0.00%	177.66%

Frequently Asked Questions About Corcept Therapeutics' Financials

When does Corcept Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Corcept Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Corcept Therapeutics' net income changed over the last 9 years?

Corcept Therapeutics' net income appears to be on an upward trend, with a most recent value of $141.21 million in 2024, falling from -$6.41 million in 2015. The previous period was $106.14 million in 2023. View Corcept Therapeutics' forecast to see where analysts expect Corcept Therapeutics to go next.

What is Corcept Therapeutics's operating income?

Corcept Therapeutics's total operating income in 2024 was $136.95 million, based on the following breakdown:

Total Gross Profit: $664.16 million
Total Operating Expenses: $527.21 million

How has Corcept Therapeutics revenue changed over the last 9 years?

Over the last 9 years, Corcept Therapeutics' total revenue changed from $50.29 million in 2015 to $675.04 million in 2024, a change of 1,242.4%.

How much debt does Corcept Therapeutics have?

Corcept Therapeutics' total liabilities were at $160.96 million at the end of 2024, a 40.2% increase from 2023, and a 381.9% increase since 2015.

How much cash does Corcept Therapeutics have?

In the past 9 years, Corcept Therapeutics' cash and equivalents has ranged from $31.06 million in 2017 to $135.55 million in 2023, and is currently $127.67 million as of their latest financial filing in 2024.

How has Corcept Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Corcept Therapeutics' book value per share changed from 0.17 in 2015 to 6.49 in 2024, a change of 3,713.2%.

Related Companies

This page (NASDAQ:CORT) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corcept Therapeutics (CORT) Financials

Frequently Asked Questions About Corcept Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corcept Therapeutics (CORT) Financials

Annual Income Statements for Corcept Therapeutics

Quarterly Income Statements for Corcept Therapeutics

Annual Cash Flow Statements for Corcept Therapeutics

Quarterly Cash Flow Statements for Corcept Therapeutics

Annual Balance Sheets for Corcept Therapeutics

Quarterly Balance Sheets for Corcept Therapeutics

Annual Metrics And Ratios for Corcept Therapeutics

Quarterly Metrics And Ratios for Corcept Therapeutics

Frequently Asked Questions About Corcept Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools